Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOs
→ For the first time since he sold Celgene to Bristol Myers Squibb for $74 billion in 2019, Mark Alles is a CEO again. Alles …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
